Main Products
Leading Pipeline Assets: GM-XANTHO • Steroid-free topical new drug for treating atopic dermatitis • Effective in treating and preventing inflammatory skin conditions • Low side effects • Phase 2a clinical trial data available • Available in large quantities with GMP/PIS specifications
Business Interests
ut-Licensing GM-XANTHO is available for out-licensing with rights in drug development and commercialization.
Contact Info
William Wu
Project Manager
+886-2-2655-7790
research@xanthobio.com